PHASE I ORAL CAPECITABINE + CISPLATIN FOR ADVANCED DIGESTIVE SYSTEM CANCERS

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。这是一项针对晚期消化系统癌症患者间歇性口服氟嘧啶卡培他滨（希罗达）并联合静脉注射顺铂的I期研究。目的是确定剂量限制性毒性、最大耐受剂量和推荐的II期剂量。将确定联合药物之间的显著相互作用。可能的抗肿瘤有效性将作为次要目标确定。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a Phase I study of oral fluoropyrimidine capecitabine (Xeloda) delivered on an intermittent scedule and combined with intravenous cisplatin in patients with advanced cancer of the digestive system. The objectives are to establish dose-limiting toxicities, maximum tolerated dose, and the recommended Phase II dose. Significant interaction between the combined agents will be determined. Possible antitumor effectiveness will be determined as a secondary objective.